Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.09 USD | -2.48% | +0.88% | -19.06% |
Sales 2024 * | 24.87M 31.4M | Sales 2025 * | 118M 149M | Capitalization | 1.06B 1.34B |
---|---|---|---|---|---|
Net income 2024 * | -75M -94.67M | Net income 2025 * | -24M -30.3M | EV / Sales 2024 * | 35.2 x |
Net cash position 2024 * | 184M 232M | Net cash position 2025 * | 146M 185M | EV / Sales 2025 * | 7.73 x |
P/E ratio 2024 * |
-28
x | P/E ratio 2025 * |
-100
x | Employees | 79 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.42% |
Latest transcript on Verona Pharma plc
1 day | -2.48% | ||
1 week | +1.00% | ||
Current month | -6.56% | ||
1 month | -10.16% | ||
3 months | -21.40% | ||
6 months | -5.02% | ||
Current year | -19.06% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 59 | 20-01-31 | |
Mark Hahn
DFI | Director of Finance/CFO | 61 | 20-02-29 |
Kavita Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mahendra Shah
BRD | Director/Board Member | 79 | 16-06-16 |
Vikas Sinha
BRD | Director/Board Member | 60 | 16-09-11 |
David Ebsworth
CHM | Chairman | 69 | 14-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.09% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 16.09 | -2.48% | 309,348 |
24-03-27 | 16.5 | +2.23% | 359,388 |
24-03-26 | 16.14 | +2.74% | 397,379 |
24-03-25 | 15.71 | -2.24% | 294,308 |
24-03-22 | 16.07 | +0.75% | 364,289 |
Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.06% | 1.34B | |
+2.73% | 108B | |
+9.59% | 104B | |
+6.58% | 23.66B | |
-12.59% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.29% | 16.19B | |
+4.68% | 13.72B | |
+34.25% | 12.22B |